CDXC News Alert Chromadex Corp (CDXC) 1.0700 09/19/2014 22:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chromadex Corp (CDXC) 1.0700 $CDXC

ChromaDex and Healthy Directions enter into NIAGEN(TM) Supply Agreement
PR Newswire - Thu Sep 11, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited (NASDAQ: HELE).

ChromaDex Names Additional Scientific Advisory Board Members
PR Newswire - Thu Sep 04, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has appointed three highly respected scientists and researchers to the company's recently formed Scientific Advisory Board (SAB): Dr. Charles Brenner, Dr. Rob Beudeker, and Dr. Bruce German.

ChromaDex® Reports Second Quarter Ingredient Sales Grew 155% Year-Over-Year and 52% Sequentially
PR Newswire - Tue Aug 12, 7:25AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014.

ChromaDex's Ryan Dellinger to Speak at 248th American Chemical Society National Meeting
PR Newswire - Wed Aug 06, 9:07AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Ryan Dellinger, Ph.D., director of scientific affairs at ChromaDex, will speak at the 248th American Chemical Society National Meeting on August 10-14.

ChromaDex® CEO to Present at 34th Annual Canaccord Genuity Growth Conference on August 13th at 8:30 am EDT
PR Newswire - Tue Aug 05, 7:30AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 34th Annual Canaccord Genuity Growth Conference to be held at the Intercontinental Boston.

ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN(TM) Research
PR Newswire - Thu Jul 31, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient for research use.

ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN(TM) Nicotinamide Riboside Will Increase NAD+
PR Newswire - Wed Jul 16, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN(TM), the first and only commercially available form of nicotinamide riboside (NR). The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited with discovery of NR as a vitamin in organisms from yeast to people as published in Cell in 2004.

Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board
PR Newswire - Tue Jul 08, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB" .

ChromaDex to evaluate natural product libraries in research partnership with St Jude Children's Research Hospital
M2 - Fri Jun 20, 7:32AM CDT
Natural products company ChromaDex (Other OTC:CDXC) revealed on Thursday that it intends to evaluate its natural product libraries in a research based partnership with St Jude Children's Research Hospital.

ChromaDex Signs Collaboration Research Agreement with St. Jude Children's Research Hospital
PR Newswire - Thu Jun 19, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.

Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging
PR Newswire - Wed Apr 02, 7:30AM CDT
Thorne Research today announced the launch of NiaCel(TM), an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel(TM) is one of the first commercially available products to feature the ingredient NIAGEN(TM) from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.

ChromaDex® Reports 2013 Full-Year Results
PR Newswire - Thu Mar 27, 5:45AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.

ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN(TM) Research
PR Newswire - Wed Mar 12, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnology Institute (GBB), a leading research institute at the University of Groningen in the Netherlands. ChromaDex will provide GBB with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient.

ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.

RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT.

Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.

ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.

International Stevia Council and ChromaDex Enter Into Agreement for Reference Benchmark Standard
PR Newswire - Wed Dec 18, 7:25AM CST
The International Stevia Council (ISC) and ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, have entered into an agreement whereby ChromaDex is to provide, for the next two years, the Reference Benchmark Standard in the ISC's Proficiency Testing Program (PTP) for stevia leaf extracts.

OTC Daily Alert Stock Watch - ChromaDex Inc. (OTCQB: CDXC)
WorldStockWire - Thu Aug 15, 9:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

ChromaDex® Reports Results for the Second Quarter 2013
PR Newswire - Tue Aug 13, 7:20AM CDT
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company" , an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the second quarter ended June 29, 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 182

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 258

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 216

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 110

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 0

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Omni-Lite Industries Reports Impressive Fiscal Q3 Results

Updated Category News Views 143

Highlights from Omni-Lite's Third Quarter Fiscal 2025 Outstanding Financial Performance Omni-Lite Industries Canada Inc. (TSXV: OML) recently reported its financial results for the third quarter of fiscal 2025, demonstrating notable growth and resilience. With revenue reaching approximately US$4.0 million, Omni-Lite saw a remarkable year-over-year increase of 7.0%...

Continue Reading
Assessing the Impact of UK Fiscal Policy on Housing Market Trends

Updated Category News Views 200

Understanding the Current UK Housing Market Dynamics The U.K. housing market is currently facing a notable slowdown, primarily driven by tax-related uncertainties associated with fiscal policies. As potential buyers adopt a more cautious stance, residential property transactions have seen a decline. This trend poses immediate risks for sectors linked to housing, including...

Continue Reading
Radford Racing School Unveils New Exciting Driving Adventures

Updated Category News Views 226

Exciting New Driving Experiences at Radford Racing School Recently, Radford Racing School, known as a leader in performance driving education, announced its latest offerings that promise to thrill automotive enthusiasts of all ages and skill levels. With the introduction of six new driving experiences, there's now something for everyone at their legendary racetrack....

Continue Reading
AppLovin CEO Sells $21.5 Million in Shares Amid Growth Momentum

Updated Category News Views 137

AppLovin CEO's Notable Stock Sale Recently, AppLovin Corp (NASDAQ: APP) made headlines with a significant financial event: CEO and Chairperson Arash Adam Foroughi sold over $21.5 million worth of company stock. According to the latest SEC filing, this noteworthy transaction occurred over just two days, with share prices varying from $98.08 to $112.33 during that time....

Continue Reading
Olverembatinib's Breakthrough Status Enhances Leukemia Treatment Options

Updated Category News Views 396

Olverembatinib Gains Breakthrough Therapy Designation Ascentage Pharma, a prominent global biopharmaceutical company, is making significant strides in the treatment of serious medical conditions. With its latest achievement, olverembatinib has secured a Breakthrough Therapy Designation in China for its use alongside low-intensity chemotherapy in newly-diagnosed patients...

Continue Reading